973 related articles for article (PubMed ID: 18724359)
1. Identification of ALK as a major familial neuroblastoma predisposition gene.
Mossé YP; Laudenslager M; Longo L; Cole KA; Wood A; Attiyeh EF; Laquaglia MJ; Sennett R; Lynch JE; Perri P; Laureys G; Speleman F; Kim C; Hou C; Hakonarson H; Torkamani A; Schork NJ; Brodeur GM; Tonini GP; Rappaport E; Devoto M; Maris JM
Nature; 2008 Oct; 455(7215):930-5. PubMed ID: 18724359
[TBL] [Abstract][Full Text] [Related]
2. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Janoueix-Lerosey I; Lequin D; Brugières L; Ribeiro A; de Pontual L; Combaret V; Raynal V; Puisieux A; Schleiermacher G; Pierron G; Valteau-Couanet D; Frebourg T; Michon J; Lyonnet S; Amiel J; Delattre O
Nature; 2008 Oct; 455(7215):967-70. PubMed ID: 18923523
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
4. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations of ALK in neuroblastoma.
Ogawa S; Takita J; Sanada M; Hayashi Y
Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma.
Devoto M; Specchia C; Laudenslager M; Longo L; Hakonarson H; Maris J; Mossé Y
Hum Hered; 2011; 71(2):135-9. PubMed ID: 21734404
[TBL] [Abstract][Full Text] [Related]
7. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
[TBL] [Abstract][Full Text] [Related]
8. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
Passoni L; Longo L; Collini P; Coluccia AM; Bozzi F; Podda M; Gregorio A; Gambini C; Garaventa A; Pistoia V; Del Grosso F; Tonini GP; Cheng M; Gambacorti-Passerini C; Anichini A; Fossati-Bellani F; Di Nicola M; Luksch R
Cancer Res; 2009 Sep; 69(18):7338-46. PubMed ID: 19723661
[TBL] [Abstract][Full Text] [Related]
9. Cancer: A ringleader identified.
Eng C
Nature; 2008 Oct; 455(7215):883-4. PubMed ID: 18923503
[No Abstract] [Full Text] [Related]
10. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
Chand D; Yamazaki Y; Ruuth K; Schönherr C; Martinsson T; Kogner P; Attiyeh EF; Maris J; Morozova O; Marra MA; Ohira M; Nakagawara A; Sandström PE; Palmer RH; Hallberg B
Dis Model Mech; 2013 Mar; 6(2):373-82. PubMed ID: 23104988
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.
Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996
[TBL] [Abstract][Full Text] [Related]
12. Effect of missense mutations on structure and interaction of anaplastic Lymphoma kinase (ALK) in neuroblastom.
Kanwal H; Khan MH; Rashid H
Pak J Pharm Sci; 2013 May; 26(3):611-6. PubMed ID: 23625438
[TBL] [Abstract][Full Text] [Related]
13. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
14. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
Bagci O; Tumer S; Olgun N; Altungoz O
Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
[TBL] [Abstract][Full Text] [Related]
15. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
16. Biological role of anaplastic lymphoma kinase in neuroblastoma.
Osajima-Hakomori Y; Miyake I; Ohira M; Nakagawara A; Nakagawa A; Sakai R
Am J Pathol; 2005 Jul; 167(1):213-22. PubMed ID: 15972965
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
18. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
20. ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.
Bourdeaut F; Ferrand S; Brugières L; Hilbert M; Ribeiro A; Lacroix L; Bénard J; Combaret V; Michon J; Valteau-Couanet D; Isidor B; Rialland X; Poirée M; Defachelles AS; Peuchmaur M; Schleiermacher G; Pierron G; Gauthier-Villars M; Janoueix-Lerosey I; Delattre O;
Eur J Hum Genet; 2012 Mar; 20(3):291-7. PubMed ID: 22071890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
